GRI Bio Investor Relations Material

GRI Bio Inc. is a biotechnology company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. The company specializes in modulating natural killer T (NKT) cells to target immune system dysregulation. Its research and development efforts aim to advance novel small-molecule drug candidates for conditions with high unmet medical needs. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.